policymed.com17h
Pfizer’s Subsidiary Biohaven Settles for Nearly $60M Over Speaker Programs: Complaint included Significant Open Payments Under Reporting
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...
Pfizer (NYSE:PFE) Stock Price Down 0.6% Following Analyst Downgrade
Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price traded down 0.6% during trading on Tuesday after Citigroup lowered their price target on the stock from $30.00 to $29.00. Citigroup currently has ...
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue ...
Royalty Pharma plc: Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including sig ...